arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BICYCLE THERAPEUTICS PLC

BCYC
$3.50 ▼ -0.21 (-5.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
37 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

BICYCLE THERAPEUTICS PLC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $244.9M
Dividend Yield —
Revenue Growth 190.2% ↗
Op. Margin -39.6%
ROIC -3.0% ↗
FCF / Share $-0.58 ↗
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.06M
↑ +190.2% —
Net Income Profit after all expenses
$-60.83M
— -0.1% —
Operating Margin Operating profit as % of sales
-39.6%
↑ +23.2% 0th
FCF / Share Free cash flow per share
$-0.58
↑ +44.0% —
Long-Term Debt Long-term obligations
$30.80M
↑ +0.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↓
21
Cash Quality ↑
71

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 10 years · 37 quarters